fbpx

Get ready for an exciting announcement for the melanoma community

  • Days
  • Hours
  • Minutes

Funded Research

About Funded Research

The MRF has funded millions of dollars in melanoma research since 1998.  Our research grants support the study of melanoma prevention, diagnosis, and treatment across the spectrum of the disease, including cutaneous, ocular, and mucosal melanoma.  The MRF Research Program supports research across their entire career- from medical students to established investigators.  The types of grants supported include:

Peer Reviewed SAC/BC/OM Grants

  • Team Awards (established in 2014) – Two-year awards, up to $250,000 per year
  • Established (Senior) Investigator Awards (established in 2006) – Two-year awards, up to $100,000 per year
  • Career Development (Junior) Awards (established in 1998) – Two-year awards, up to $50,000 per year
  • Pilot Awards (established in 2022) – One-year awards, up to $50,000
  • Resident/Fellow Awards (established in 2024) – One-year awards, up to $10,000
  • Medical Student Awards (established in 2011) – One-year awards, up to $3,000
  •  

Research Awards

  • ASCO/Conquer Cancer Endowed Merit Award (sponsored by the MRF since 2023) – One-year awards, $10,000 per year
  • Society for Melanoma Research Young Investigator Award (sponsored by the MRF since 2013) – One-year awards, $5,000 per year
  • Society for Melanoma Research Christopher J. Marshall Award (sponsored by the MRF since 2015) – One-year awards, $5,000 per year
  • Donor-directed – donor awards to fund specific areas of melanoma research

 

Occasionally, we also have special opportunities available that do not adhere to our usual categories.

Filter by State, Melanoma Type, Year, and Grant Category

Melanoma Type

Year

Grant Category

2020 Research Grants

Shruthy Suresh, PhD

Shruthy Suresh, PhD

Memorial Sloan Kettering Cancer Center

2024 Research Grants

Alondra Valencia

Alondra Valencia

Design of sun protection/melanoma prevention materials in LatinX caregivers

Vanessa Weir

Vanessa Weir

The Relationship Between Skin Tone and Molecular Alterations in Melanoma

Tissiana Vallecillo

Tissiana Vallecillo

Frozen Section of Melanoma: Accuracy at an Experienced Institution

Kaden Thomas

Kaden Thomas

A Barbershop Intervention to Improve Melanoma Detection in Rural US

Load-More

2023 Research Grants

Bruce Ksander, PhD

Bruce Ksander, PhD

Identification of molecular pathways that drive uveal melanoma metastasis

Kristen Richards, MD

Kristen Richards, MD

Evaluation of cutaneous immune related adverse events by morphotype

Xiaonan Xu, MD, PhD

Xiaonan Xu, MD, PhD

Understand metastasis of uveal melanoma in vivo via novel mouse models

Lilit Karapetyan, MD

Lilit Karapetyan, MD

Deciphering the role of APRIL/TNFSF13 in melanoma-associated TLS formation

Load-More

2022 Research Grants

Leslie K. Dennis, PhD, MS

Leslie K. Dennis, PhD, MS

How melanoma patients undergoing treatment at oncology practices are affected by having a positive COVID-19 test

Emily Bernstein, PhD

Emily Bernstein, PhD

Chromatin Remodeling Alterations and Consequences for Melanoma Metastasis

Hilary Coller, PhD

Hilary Coller, PhD

Noncanonical Autophagy Inhibition as a New Approach to Melanoma Therapy

Brent Hanks, MD, PhD

Brent Hanks, MD, PhD

Role of the Gli2 Pathway in Melanoma Immunotherapy Resistance

Load-More

2021 Research Grants

Mackenzie Wehner, MD, MPhil

Mackenzie Wehner, MD, MPhil

Melanoma Risks and Risk Prediction in Patients with Actinic Keratosis

Nicolas Vabret, PhD

Nicolas Vabret, PhD

Harnessing Epigenetic therapies to License Melanoma Vaccine

Jessalyn Ubellacker, PhD

Jessalyn Ubellacker, PhD

Targeting metabolic vulnerabilities of melanoma metastasis in lymph

Colt Egelston, PhD

Colt Egelston, PhD

Immunotherapy using personalized T cell receptor engineered T cells

Load-More

2020 Research Grants

Diwakar Davar, MD

Diwakar Davar, MD

Integrative Analysis of Prognostic Factors to Neoadjuvant Nivolumab/CMP-001 in Stage III B/C/D Melanoma

Linda Malkas, PhD

Linda Malkas, PhD

Novel Target for Melanoma Therapeutic Development

Thorsten Mempel, MD, PhD

Thorsten Mempel, MD, PhD

Converting Regulatory into Proinflammatory Anti-Tumor Effector T Cells

Jeffrey Ravetch, MD, PhD

Jeffrey Ravetch, MD, PhD

Defining the Mechanisms of Resistance to Anti-CTLA4 Antibodies in the TME

Load-More